Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LY3002815 in Healthy Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: LY3002815
Drug: Placebo

First Posted Date: 2017-05-11

Last Posted Date: 2018-11-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 45

Registration Number: NCT03148431

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, UK, United Kingdom

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: tirzepatide
Drug: Dulaglutide
Drug: Placebo

First Posted Date: 2017-04-27

Last Posted Date: 2019-08-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 318

Registration Number: NCT03131687

Locations: 🇸🇰
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Trenčín, Slovakia
🇸🇰
"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", Trenčín, Slovakia
🇺🇸
National Research Institute, Los Angeles, California, United States

and more 38 locations

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

Phase 3

Completed

Conditions: Axial Spondyloarthritis

Interventions: Drug: Ixekizumab
Drug: Placebo

First Posted Date: 2017-04-26

Last Posted Date: 2022-06-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 773

Registration Number: NCT03129100

Locations: 🇺🇸
Physician Research Collaboration, LLC, Lincoln, Nebraska, United States
🇺🇸
Arthritis Rheumatic Disease Specialties, Aventura, Florida, United States
🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada

and more 123 locations

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Phase 1

Completed

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Olaratumab
Drug: Pembrolizumab (KEYTRUDA®)

First Posted Date: 2017-04-24

Last Posted Date: 2024-10-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT03126591

Locations: 🇫🇷
Gustave Roussy, Villejuif Cedex, France
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇧🇪
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium

and more 3 locations

A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY3325656
Drug: Placebo
Drug: Liraglutide
Drug: Sitagliptin

First Posted Date: 2017-04-14

Last Posted Date: 2018-08-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 80

Registration Number: NCT03115099

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
🇸🇬
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Singapore, Singapore

A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: LY3321367
Drug: LY3300054

First Posted Date: 2017-04-04

Last Posted Date: 2023-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 209

Registration Number: NCT03099109

Locations: 🇪🇸
Fundación Jiménez Díaz-Oncology, Madrid, Spain
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇰🇷
Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of

and more 12 locations

A Study of LY3337641 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Reference Formulation (R)
Drug: LY3337641 (T1)
Drug: LY3337641 (T2)

First Posted Date: 2017-04-04

Last Posted Date: 2023-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT03099148

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
🇸🇬
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Singapore, Singapore

A Study of AK-01 (LY3295668) in Solid Tumors

Phase 1

Completed

Conditions: Neoplasms
Neoplasm Metastasis
Triple Negative Breast Neoplasms
Head and Neck Neoplasms
Breast Neoplasms
Solid Tumor, Adult
Small Cell Lung Carcinoma

Interventions: Drug: LY3295668

First Posted Date: 2017-03-28

Last Posted Date: 2021-07-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 13

Registration Number: NCT03092934

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
McGill University, Montreal, Quebec, Canada
🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Olaratumab
Drug: Nab-paclitaxel
Drug: Placebo
Drug: Gemcitabine

First Posted Date: 2017-03-22

Last Posted Date: 2022-06-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 184

Registration Number: NCT03086369

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

and more 31 locations

A Study of LY3337641 in Japanese and Caucasian Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3337641
Drug: Placebo

First Posted Date: 2017-03-20

Last Posted Date: 2023-08-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT03083561

Locations: 🇺🇸
WCCT Global, Cypress, California, United States

Home Terms & Conditions Privacy Policy